THE OTHER SIDE OF POSSIBLE

A FUNDAMENTALLY DIFFERENT APPROACH TO TREATING CANCER & RARE GENETIC DISEASES

Inspired by patients and frustrated by the limitations of conventional approaches to treatment, Agios pioneered a novel path to treating cancer and rare genetic diseases by targeting cellular metabolism. In our first decade, Agios brought two precision oncology medications from our own labs to patients – TIBSOVO® (ivosidenib tablets) for acute myeloid leukemia (AML) patients with an IDH1 mutation and IDHIFA® (enasidenib) for AML patients with an IDH2 mutation. During that same time period, the Agios team discovered and developed six additional investigational new drug (IND) candidates, including the first pyruvate kinase-R (PKR) activator in development as a potential treatment for a rare hemolytic anemia known as pyruvate kinase deficiency. Agios is leading the way in advancing PKR activation for additional non-malignant hematologic diseases, including thalassemia and sickle cell disease, and the company continues to foster a productive research engine that yields new insights and potential therapeutic approaches. Now entering our next decade, Agios has a differentiated portfolio of preclinical, clinical and commercial programs, unparalleled expertise in cellular metabolism and a committed team that will continue to drive the company’s mission to make a difference for patients with hematologic malignancies, solid tumors and rare genetic diseases.

UNAVERSING COMMITMENT TO SCIENCE AND PATIENTS

Agios is a biopharmaceutical company passionately committed to applying our leadership in the field of cellular metabolism to transform the lives of patients with hematologic malignancies, solid tumors and rare genetic diseases. Metabolism is a complex biological process involving the uptake and assimilation of nutrients in cells to produce energy and facilitate many of the processes required for cellular division and growth. Agios believes that dysregulation of normal cellular metabolism plays a crucial role in many genetic diseases, and it is among the first in using cellular metabolism as a platform for developing potentially transformative medicines.

VISION

Agios is passionately committed to applying our leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.

LEADERSHIP TEAM

Jacqualyn Fouse, Ph.D.
Chief Executive Officer

Jonathan Biler
Chief Legal Officer

Chris Bowden, M.D.
Chief Medical Officer

Bruce Car, Ph.D.
Chief Scientific Officer

Andrew Hirsch
Chief Financial Officer and Head of Corporate Development

Melissa McLaughlin
Chief People Officer

Darrin Miles
SVP U.S. Commercial and Global Marketing

Orlando Oliveira
SVP and General Manager, International

Clive Patience, Ph.D.
EVP Technical Operations

CONTACT INFORMATION

AGIOS
88 Sidney Street
Cambridge, MA 02139-4169
617-649-8600 | www.agios.com | info@agios.com

INVESTORS CONTACT
Holly Manning
Director, Investor Relations
617-844-6630 | Holly.Manning@agios.com

MEDIA CONTACT
Jessica Rennekamp
Associate Director, Corporate Communications
857-209-3286 | Jessica.Rennekamp@agios.com

10 YEARS

Productive Research Engine | Creative Clinical Development | Patient-centric Approach | “Other Side Of Possible” Culture

8 | 70+ | 15+ | 1,500+

Investigational New Drug Candidates | Peer-reviewed Publications | Research Programs | Patients Treated in our Clinical Trials

2 | 4 | ~550

Medicines Approved | Additional Molecules in Clinical Development | High Caliber Employees with 1 Vision

Last updated June 2020
**CLINICAL PROGRAMS**

<table>
<thead>
<tr>
<th>INDICATION</th>
<th>DRUG DISCOVERY</th>
<th>EARLY STAGE CLINICAL DEVELOPMENT</th>
<th>LATE STAGE CLINICAL DEVELOPMENT</th>
<th>REGULATORY SUBMISSION</th>
<th>APPROVED</th>
<th>PROGRAM RIGHTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>R/R AML</td>
<td></td>
<td>Phase 1 Drug Evaluation</td>
<td>Phase 3 Dose-Escalation and Expansion</td>
<td>EU</td>
<td>U.S.</td>
<td>-</td>
</tr>
<tr>
<td>Frontline AML Monotherapy</td>
<td></td>
<td>Phase 1 Drug Evaluation</td>
<td>Phase 3 Dose-Escalation and Expansion</td>
<td>U.S.</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IC-Eligible Frontline AML</td>
<td></td>
<td>Phase 1b 7+3 Combo</td>
<td>Phase 5 HOVON 7×3 Combo</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IC-Ineligible Frontline AML</td>
<td></td>
<td>Phase 1/2 Azacitidine Combo</td>
<td>Phase 3 AGILE Azacitidine Combo</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Cholangio</td>
<td></td>
<td>Phase 1 Drug Evaluation</td>
<td>Phase 3 ClariDhy</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>R/R MDS</td>
<td></td>
<td>Phase 1 Expansion</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>R/R AML</td>
<td></td>
<td>Phase 3 IDENTIFY</td>
<td>U.S.</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IC-Eligible Frontline AML</td>
<td></td>
<td>Phase 1b 7+3 Combo</td>
<td>Phase 5 HOVON 7×3 Combo</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IC-Ineligible Frontline AML</td>
<td></td>
<td>Phase 1/2 Azacitidine Combo</td>
<td>Phase 3 AGILE Azacitidine Combo</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PK Deficiency—Not Regularly Transfused</td>
<td></td>
<td>Phase 2 DRIVE PK</td>
<td>Phase 3 ACTIVATE</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>PK Deficiency—Regularly Transfused</td>
<td></td>
<td>Phase 2 DRIVE PK</td>
<td>Phase 3 ACTIVATE</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thalassemia</td>
<td></td>
<td>Phase 2 Study</td>
<td>Phase 3 INDIGO</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Low-Grade Glioma</td>
<td></td>
<td>Perioperative Study</td>
<td>Phase 3 INDIGO</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>R/R MDS</td>
<td></td>
<td>Phase 3 IDENTIFY</td>
<td>U.S.</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IC-Eligible Frontline AML</td>
<td></td>
<td>Phase 1b 7+3 Combo</td>
<td>Phase 5 HOVON 7×3 Combo</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>IC-Ineligible Frontline AML</td>
<td></td>
<td>Phase 1/2 Azacitidine Combo</td>
<td>Phase 3 AGILE Azacitidine Combo</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Mitapivat (PKR Activator)</td>
<td></td>
<td>Phase 2 DRIVE PK</td>
<td>Phase 3 ACTIVATE</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Thalassemia</td>
<td></td>
<td>Phase 2 Study</td>
<td>Phase 3 INDIGO</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Vorasidenib (Pan-Oncin Inhibitor)</td>
<td></td>
<td>Perioperative Study</td>
<td>Phase 3 INDIGO</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>AG-270 (MAT2A Inhibitor)</td>
<td></td>
<td>Phase 1 Dose-Escalation and Expansion</td>
<td>Phase 3 IDENTITY</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>AG-946 (PKR Activator)</td>
<td></td>
<td>Phase 1 Planned</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

**TIBSOVO® (ivosidenib Tablets)**

Is an investigational, wholly owned, first-in-class, novel, oral activator of both wild-type and mutated PKR enzymes. The initial focus of the AG-946 development program is to establish that it is safe and well-tolerated in healthy volunteers.

**IDHIFA® (enasidenib)**

Is an investigational, orally available, selective inhibitor of the mutated IDH1 and IDH2 enzymes. In early clinical studies, vorasidenib demonstrated full blood-brain barrier penetration, robust suppression of the oncometabolite 2-HG and encouraging preliminary efficacy. Vorasidenib is currently being studied in the registration-enabling Phase 3 INDIGO study in patients with IDH-mutant low-grade glioma.

**Mitapivat (PKR Activator)**

Is an investigational, wholly owned, first-in-class, novel, oral activator of both wild-type and mutated PKR enzymes. Mitapivat is a next-generation oral activator of both wild-type and mutated PKR enzymes. The initial focus of the AG-946 development program is to establish that it is safe and well-tolerated in healthy volunteers.

**PRECLINICAL PROGRAMS**

Agios has led the field of cancer metabolism with its novel IDH and MTAP programs and continues to make important advances in the field of rare genetic diseases with its PKR program. These programs exemplify our strategy of applying our foundational expertise in cellular metabolism and precision medicine to translate science from our labs into first-of-their-kind experimental therapies. In addition to advancing our lead programs, we continue to discover novel metabolic targets that meet a high bar for future development across all three of our core focus areas: malignant hematology, solid tumors and rare genetic diseases.

**NOTICE**

Cautionary Note Regarding Forward-Looking Statements

This fact sheet contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding Agios’ plans, strategies and expectations for its and its collaborators’ preclinical, clinical and commercial advancement of its drug development programs including IDHIFA® (enasidenib), TIBSOVO® (ivosidenib tablets), vorasidenib, mitapivat, AG-270 and AG-946, the potential benefits of Agios’ product candidates, and the potential benefit of its strategic plans and focus. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would,” “could,” “potential,” “possible,” “hope” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios’ product candidates will successfully continue. There can be no guarantee that any positive developments in Agios’ business will result in stock price appreciation. Management’s expectations and, therefore, any forward-looking statements in this fact sheet could also be affected by risks and uncertainties relating to a number of other important factors including, without limitation: risks and uncertainties related to the impact of the COVID-19 pandemic to Agios’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios’ results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions required by law.

Such forward-looking statements include those regarding Agios’ plans, strategies and expectations for its and its collaborators’ preclinical, clinical and commercial advancement of its drug development programs including IDHIFA® (enasidenib), TIBSOVO® (ivosidenib tablets), vorasidenib, mitapivat, AG-270 and AG-946, the potential benefits of Agios’ product candidates, and the potential benefit of its strategic plans and focus. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would,” “could,” “potential,” “possible,” “hope” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from Agios’ current expectations and beliefs. For example, there can be no guarantee that any product candidate Agios is developing will successfully commence or complete necessary preclinical and clinical development phases, or that development of any of Agios’ product candidates will successfully continue. There can be no guarantee that any positive developments in Agios’ business will result in stock price appreciation. Management’s expectations and, therefore, any forward-looking statements in this fact sheet could also be affected by risks and uncertainties relating to a number of other important factors including, without limitation: risks and uncertainties related to the impact of the COVID-19 pandemic to Agios’ business, operations, strategy, goals and anticipated milestones, including its ongoing and planned research activities, ability to conduct ongoing and planned clinical trials, clinical supply of current or future drug candidates, commercial supply of current or future approved products, and launching, marketing and selling current or future approved products; Agios’ results of clinical trials and preclinical studies, including subsequent analysis of existing data and new data received from ongoing and future studies; the content and timing of decisions required by law.

**AGIOS CORPORATION**

The safety and efficacy of the agents and uses under investigation have not been established. There is no guarantee that the agents will receive health authority approval or become commercially available in any country for the uses being investigated.